Two investigational treatments, solanezumab and gantenerumab, failed to prevent memory loss or cognitive decline in patients with a rare, inherited form of early-onset Alzheimer’s disease, who were enrolled in a Phase 2/3 clinical trial (NCT01760005). Despite these results, the data collected will prove useful for identifying…
Biogen will soon launch an open-label trial to start re-dosing aducanumab — an injectable treatment under development — to patients with Alzheimer’s disease who participated in four studies halted in March 2019. The company said it submitted the protocol of the re-dosing study to the U.S.
The number of people with dementia in 37 countries in and near Europe is likely to double to 18.8 million by 2050, according to Alzheimer Europe. That’s more than the 18 million predicted in previous forecasts. The Luxembourg-based organization also lowered estimates of the current dementia count by a…
Following feedback from the U.S. Food and Drug Administration (FDA), Cortexyme will conduct an interim analysis for effectiveness of its lead investigational therapy COR388, currently in the Phase 2/3 GAIN trial for treatment of mild to moderate Alzheimer’s disease. The analysis, expected to be finished by the end…
Using the gene editing technology CRISPR-Cas9 like a pair of “DNA scissors,” researchers were able to essentially cut out the beta-secretase 1 (BACE1) gene in a mouse model of Alzheimer’s disease, a study shows. Deleting this gene — which drives the production of amyloid-β proteins in…
A molecular chaperone called TPT-172 was able to prevent proteins linked to Alzheimer’s — including amyloid-beta and tau — from building up in the brain, improve memory and ease brain inflammation when tested in a mouse model of the disease. The study, “A pharmacological chaperone improves memory by…
The United Kingdom has awarded Memory Health a patent for a proprietary brain health supplement developed to prevent and treat neurodegenerative disease. Also called Memory Health, the all-natural nutritional supplement is made especially for Alzheimer’s disease (AD) and dementia patients. The company is the sole licensee…
The National Institutes of Health (NIH) has awarded a $4.8-million grant to support a project designed to discover how the ApoE4 gene variant, a known genetic risk factor for late-onset Alzheimer’s disease, induces neurodegeneration. The apolipoprotein E (ApoE) proteins encoded by the APOE gene…
Physicians, industry representatives, and Alzheimer’s disease patients urged lawmakers in Washington to pass legislation they say will improve access to amyloid positron imaging tomography (PET) scans for the diagnosis, research and treatment of Alzheimer’s. The Medical Imaging & Technology Alliance(MITA), the Council on…
A Phase 1b trial has started dosing Alzheimer’s patients with Alector’s candidate immune system-targeting therapy, called AL003, to evaluate its safety and tolerability, the company has announced. AL003 is an antibody which targets sialic acid binding Ig-like lectin 3 (SIGLEC 3, also known as CD33). SIGLEC 3 is…
Get regular updates to your inbox.